By 2030, spending on treating cardiovascular disease is expected to triple to $818.1 billion from $272.5 billion in 2010, according to an American Heart Association policy statement published in the organization's journal Circulation. Hypertension is expected to be the most expensive component of that treatment, the statement noted. (Financial figures are given in 2008 dollars.)
Cardio costs likely to triple: Heart association
Cardiovascular disease is the leading cause of death in the U.S. and accounts for 17% of national healthcare expenditures, according to the 13-page statement. The AHA also notes that the growth in costs has been accompanied by longer life expectancy and suggests that, as a result, "this spending was of value."
The greatest projected costs are linked to hypertension and its "downstream diseases," whose costs are double that of hypertension itself, the statement's authors note. Reversing obesity trends can play a "pivotal role" in reducing hypertension spending, as can simple measures such as reducing sodium intake, according to the statement.
"Through a combination of improved prevention of risk factors and treatment of established risk factors, the dire projection of the health and economic impact” of cardiovascular disease can be diminished, the statement concluded.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.